1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended September 30, 2025.
−Removed: No trading arrangements were terminated by our directors and executive officers during the quarter ended September 30, 2025.
+Added: The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended March 31, 2026.
+Added: No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2026.
Trading Arrangement
3 unchanged sentences
Shares to be Sold Expiration
−Removed: Jonathan Slonin
−Removed: Chief Medical Officer
+Added: Brendan Teehan
+Added: Chief Commercial Officer
Adopt 3/5/2026 x 8,720 (1)
−Removed: Kristen Williams
−Removed: Chief Administrative Officer and Secretary
+Added: Principal Accounting Officer
Adopt 3/12/2026 x To Be Determined (2)
1 unchanged sentence
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
−Removed: (1) The aggregate number of shares to be sold pursuant to the trading arrangements listed above are dependent on, among other things, sale prices under the trading arrangements and the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.
−Removed: Pacira BioSciences, Inc.
−Removed: | Q3 2025 Form 10-Q | 61
+Added: (1) The shares to be sold pursuant to the trading arrangement listed above are dependent on sale prices under the trading arrangement.
+Added: (2) The aggregate number of shares to be sold pursuant to the trading arrangement listed above is dependent on, among other things, sale prices under the trading arrangement and the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.
The exhibits listed below are filed or furnished as part of this report.
Exhibit Number Description
−Removed: Credit Agreement, dated as of July 3, 2025, by and among Pacira BioSciences, Inc., the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent, swingline lender and an issuing bank.(1) ##
+Added: Form of Performance Share Unit Agreement under the Amended and Restated 2011 Stock Incentive Plan.* ***
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
3 unchanged sentences
101 The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc.
−Removed: for the quarter ended September 30, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: for the quarter ended March 31, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) the Condensed Consolidated Balance Sheets;
(ii) the Condensed Consolidated Statements of Operations;
−Removed: (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss);
+Added: (iii) the Condensed Consolidated Statements of Comprehensive Income;
(iv) the Condensed Consolidated Statements of Stockholders’ Equity;
5 unchanged sentences
*** Denotes management contract or compensatory plan or arrangement.
−Removed: ## Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
−Removed: The Company hereby undertakes to supplementally furnish copies of any omitted schedules and exhibits to the Securities and Exchange Commission upon request.
−Removed: (1) Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on July 7, 2025.
Pacira BioSciences, Inc.
−Removed: | Q3 2025 Form 10-Q | 62
+Added: | Q1 2026 Quarterly Report on Form 10-Q | 49
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PACIRA BIOSCIENCES, INC.
−Removed: November 6, 2025 By:
+Added: April 30, 2026 By:
Chief Executive Officer and Director
(Principal Executive Officer)
−Removed: November 6, 2025 By:
+Added: April 30, 2026 By:
Chief Financial Officer
1 unchanged sentence
Pacira BioSciences, Inc.
−Removed: | Q3 2025 Form 10-Q | 63
+Added: | Q1 2026 Quarterly Report on Form 10-Q | 50
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.